Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers

• Tipo: Artigo em Revista Científica Internacional
• Data: 2024

Autores

Ramos, A (Autor) Outra; Martins, S (Autor) Outra; Marinho, AS (Autor) Outra; Norton, P (Autor) Outra; Cardoso, MJ (Autor) Outra; guimaraes, jt (Autor) FMUP

Revista

Título: PLoS ONE

Vol. 19

ISSN: 1932-6203

Editora: Public Library of Science

Indexação

ISI Web of Knowledge - 0 Citações

Scopus - 0 Citações

Outras Informações

ID Authenticus: P-010-EF6

DOI: 10.1371/journal.pone.0303244

Abstract (EN): To predict protective immunity to SARS-CoV-2, cellular immunity seems to be more sensitive than humoral immunity. Through an Interferon-Gamma (IFN-gamma) Release Assay (IGRA), we show that, despite a marked decrease in total antibodies, 94.3% of 123 healthcare workers have a positive cellular response 6 months after inoculation with the 2nd dose of BNT162b2 vaccine. Despite the qualitative relationship found, we did not observe a quantitative correlation between IFN-gamma and IgG levels against SARS-CoV-2. Using stimulated whole blood from a subset of participants, we confirmed the specific T-cell response to SARS-CoV-2 by dosing elevated levels of the IL-6, IL-10 and TNF-alpha. Through a 20-month follow-up, we found that none of the infected participants had severe COVID-19 and that the first positive cases were only 12 months after the 2nd dose inoculation. Future studies are needed to understand if IGRA-SARS-CoV-2 can be a powerful diagnostic tool to predict future COVID-19 severe disease, guiding vaccination policies.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 13